Advances in lipid-based nanocarriers for breast cancer metastasis treatment.

Joun, I; Nixdorf, S; Deng, W

Advances in lipid-based nanocarriers for breast cancer metastasis treatment.

Joun, I Nixdorf, S Deng, W

Permalink

Publisher:: Frontiers
Publication Type:: Journal Article
Citation:: Front Med Technol, 2022, 4, pp. 893056
Issue Date:: 2022

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download full textAdobe PDF (1.53 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Joun, I
dc.contributor.author	Nixdorf, S
dc.contributor.author	Deng, W https://orcid.org/0000-0002-9413-0978
dc.date.accessioned	2023-03-10T09:19:08Z
dc.date.available	2022-08-02
dc.date.available	2023-03-10T09:19:08Z
dc.date.issued	2022
dc.identifier.citation	Front Med Technol, 2022, 4, pp. 893056
dc.identifier.issn	2673-3129
dc.identifier.issn	2673-3129
dc.identifier.uri	http://hdl.handle.net/10453/166984
dc.description.abstract	Breast cancer (BC) is the most common cancer affecting women worldwide, with over 2 million women diagnosed every year, and close to 8 million women currently alive following a diagnosis of BC in the last 5-years. The side effects such as chemodrug toxicity to healthy tissues and drug resistance severely affect the quality of life of BC patients. To overcome these limitations, many efforts have been made to develop nanomaterial-based drug delivery systems. Among these nanocarriers, lipid-based delivery platforms represented one of the most successful candidates for cancer therapy, improving the safety profile and therapeutic efficacy of encapsulated drugs. In this review we will mainly discuss and summarize the recent advances in such delivery systems for BC metastasis treatment, with a particular focus on targeting the common metastatic sites in bone, brain and lung. We will also provide our perspectives on lipid-based nanocarrier development for future clinical translation.
dc.format	Electronic-eCollection
dc.language	eng
dc.publisher	Frontiers
dc.relation	http://purl.org/au-research/grants/nhmrc/1181889
dc.relation.ispartof	Front Med Technol
dc.relation.isbasedon	10.3389/fmedt.2022.893056
dc.rights	info:eu-repo/semantics/openAccess
dc.title	Advances in lipid-based nanocarriers for breast cancer metastasis treatment.
dc.type	Journal Article
utslib.citation.volume	4
utslib.location.activity	Switzerland
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
utslib.copyright.status	open_access	*
dc.date.updated	2023-03-10T09:19:03Z
pubs.publication-status	Published online
pubs.volume	4

Abstract:

Breast cancer (BC) is the most common cancer affecting women worldwide, with over 2 million women diagnosed every year, and close to 8 million women currently alive following a diagnosis of BC in the last 5-years. The side effects such as chemodrug toxicity to healthy tissues and drug resistance severely affect the quality of life of BC patients. To overcome these limitations, many efforts have been made to develop nanomaterial-based drug delivery systems. Among these nanocarriers, lipid-based delivery platforms represented one of the most successful candidates for cancer therapy, improving the safety profile and therapeutic efficacy of encapsulated drugs. In this review we will mainly discuss and summarize the recent advances in such delivery systems for BC metastasis treatment, with a particular focus on targeting the common metastatic sites in bone, brain and lung. We will also provide our perspectives on lipid-based nanocarrier development for future clinical translation.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/166984